Drugs / HC002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06670274 | Nov 2024 → Mar 2025 | autoimmune disease, inflammatory disease | Holoclara Aus Pty Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HC002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06670274 ↗ |
| Route | Oral | “Route of administration: Oral” NCT06670274 ↗ |